智通财经APP讯，莱美药业(300006.SZ)发布2022年年度报告，该公司营业收入为8.85亿元，同比减少27.80%。归属于上市公司股东的净亏损为6870.91万元，同比收窄31.65%。归属于上市公司股东的扣除非经常性损益的净亏损为1.15亿元，同比收窄16.43%。基本每股亏损为0.0651元。
2022年度业绩亏损主要受国家集采政策、继续保持较大研发投入等综合因素影响。受国家集采政策影响，公司重点产品艾司奥美拉唑肠溶胶囊销量及销售单价进一步下滑，销售收入及利润相应减少;因报告期内部分地区物流停运，住院需求下降，对公司相关产品发货和销售也造成一定程度的影响。
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.
